Assessing the serum chymase level as an early predictor of dengue severity.
biomarker
chymase
dengue
predictors
severe disease
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
10
08
2020
received:
18
04
2020
accepted:
25
08
2020
pubmed:
29
8
2020
medline:
9
10
2021
entrez:
29
8
2020
Statut:
ppublish
Résumé
We conducted a prospective, observational study to assess the serum chymase level, a mast cell derived protease, as a predictor of dengue severity. NS1-positive non-severe dengue patients of age ≥14 years with duration of fever ≤4 days were included in the study. At the time of admission, the serum sample was taken for chymase estimation. Patients were followed up to four days after they became afebrile to find out the final diagnosis. Total of 338 non-severe dengue patients were recruited (mean age: 29.15 years; male: 66%). On follow-up, 26 patients (7.8%) developed severe dengue. Only chymase level (adjusted odds ratio [aOR]: 1.787; 95% confidence interval [CI]: 1.309-2.440) and platelet count at admission (aOR: 0.981; 95% CI: 0.968-0.993) were able to predict the severity after adjustment for all variables. But, for prediction of severe dengue, the area under receiver's operating curve of chymase was 0.835 (95% CI: 0.765-0.905), which was significantly higher than that of the platelet count at admission (0.760, 95% CI: 0.650-0.870) (p < .001). Patients who developed severe dengue in due course of illness had significantly higher serum chymase level at admission as compared with the rest of the patients. Similar findings were noted across all age-groups. At an optimum cut-off value of 1.35 ng/ml, chymase had a positive likelihood ratio (LR) of 3.5 and a negative LR of 0.15, for predicting severe dengue. This study demonstrated the potential ability of serum chymase levels at admission, as a biomarker for prediction of severe dengue in due course of illness.
Substances chimiques
Biomarkers
0
Chymases
EC 3.4.21.39
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
3330-3337Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Wilder-Smith A, Gubler DJ, Weaver SC, Monath TP, Heymann DL, Scott TW. Epidemic arboviral diseases: priorities for research and public health. Lancet Infect Dis. 2017;17(3):e101-e106. https://doi.org/10.1016/S1473-3099(16)30518-7
Rigau-Pérez JG, Clark GG, Gubler DJ, Reiter P, Sanders EJ, Vorndam AV. Dengue and dengue haemorrhagic fever. Lancet. 1998;352(9132):971-977. https://doi.org/10.1016/s0140-6736(97)12483-7
World Health Organisation (2009). Dengue guidelines for diagnosis, treatment, prevention and control: new edition World Health Organization; 2020. https://apps.who.int/iris/handle/10665/44188. Accessed February 20, 2020.
Yacoub S, Wills B. Predicting outcome from dengue. BMC Med. 2014;12(1):147. https://doi.org/10.1186/s12916-014-0147-9
John DV, Lin Y-S, Perng GC. Biomarkers of severe dengue disease-a review. J Biomed Sci. 2015;22(1):83. https://doi.org/10.1186/s12929-015-0191-6
St John AL, Rathore AP, Raghavan B, Ng M-L, Abraham SN. Contributions of mast cells and vasoactive products, leukotrienes and chymase, to dengue virus-induced vascular leakage. eLife. 2013;2:e00481. https://doi.org/10.7554/eLife.00481
Cusabio Technology LLC. Human mast cell chymase ELISA kit. 2020. https://www.cusabio.com/ELISA-Kit/Human-Mast-Cell-Chymase-ELISA-Kit-71718.html. Accessed February 20, 2020.
Hajian-Tilaki K. The choice of methods in determining the optimal cut-off value for quantitative diagnostic test evaluation. Stat Methods Med Res. 2018;27(8):2374-2383. https://doi.org/10.1177/0962280216680383
Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32-35. https://doi.org/10.1002/1097-0142(1950)3:13.0.CO;2-3
Tissera HA, Rathore APS, Yee LW, et al. Chymase level is a predictive biomarker of dengue hemorrhagic fever in pediatric and adult patients. J Infect Dis. 2017;216(9):1112-1121. https://doi.org/10.1093/infdis/jix447
Furuta T, Murao LA, Lan NTP, et al. Association of mast cell-derived VEGF and proteases in dengue shock syndrome. PLOS Negl Trop Dis. 2012;6(2):e1505. https://doi.org/10.1371/journal.pntd.0001505
Inokuchi M, Dumre SP, Mizukami S, et al. Association between dengue severity and plasma levels of dengue-specific IgE and chymase. Arch Virol. 2018;163(9):2337-2347. https://doi.org/10.1007/s00705-018-3849-z
Rathore APS, Senanayake M, Athapathu AS, et al. Serum chymase levels correlate with severe dengue warning signs and clinical fluid accumulation in hospitalized pediatric patients. Sci Rep. 2020;10. https://doi.org/10.1038/s41598-020-68844-z
Sherif NA, Zayan AH, Elkady AH, et al. Mast cell mediators in relation to dengue severity: a systematic review and meta-analysis. Rev Med Virol. 2020;30(1). https://doi.org/10.1002/rmv.2084
Molinaro AM. Diagnostic tests: how to estimate the positive predictive value. Neurooncol Pract. 2015;2(4):162-166. https://doi.org/10.1093/nop/npv030
Bodinayake CK, Tillekeratne LG, Nagahawatte A, et al. Evaluation of the WHO 2009 classification for diagnosis of acute dengue in a large cohort of adults and children in Sri Lanka during a dengue-1 epidemic. PLOS Neglected Trop Dis. 2018;12(2):e0006258. https://doi.org/10.1371/journal.pntd.0006258
Horstick O, Jaenisch T, Martinez E, et al. Comparing the usefulness of the 1997 and 2009 WHO dengue case classification: a systematic literature review. Am J Trop Med Hyg. 2014;91(3):621-634. https://doi.org/10.4269/ajtmh.13-0676